The Latest Headlines at American Banking and Market News
Cognex (NASDAQ:CGNX) Upgraded to Buy by HSBC
HSBC upgraded shares of Cognex (NASDAQ:CGNX – Free Report) from a hold rating to a buy rating in a report issued on Tuesday morning, MarketBeat Ratings reports. The brokerage currently has $52.00 target price on the scientific... More of this article »
Cognex’s (CGNX) “Buy” Rating Reaffirmed at Truist Financial
Truist Financial reaffirmed their buy rating on shares of Cognex (NASDAQ:CGNX – Free Report) in a research report released on Tuesday, Benzinga reports. The firm currently has a $50.00 target price on the scientific and technical... More of this article »
CASI Pharmaceuticals (NASDAQ:CASI) Receives New Coverage from Analysts at StockNews.com
StockNews.com began coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Free Report) in a report published on Tuesday. The brokerage issued a hold rating on the biotechnology company’s stock. CASI Pharmaceuticals... More of this article »-logo.png?v=20230920074015&w=240&h=220&zc=2){kind=logo}
Maplebear (NASDAQ:CART) Given “Hold” Rating at Needham & Company LLC
Needham & Company LLC reaffirmed their hold rating on shares of Maplebear (NASDAQ:CART – Free Report) in a report published on Tuesday morning, Benzinga reports. CART has been the topic of several other reports. Macquarie... More of this article »
BioNTech (NASDAQ:BNTX) Price Target Lowered to $122.00 at BMO Capital Markets
BioNTech (NASDAQ:BNTX – Free Report) had its target price reduced by BMO Capital Markets from $123.00 to $122.00 in a research report report published on Tuesday, Benzinga reports. BMO Capital Markets currently has an outperform... More of this article »
Maplebear (NASDAQ:CART) Receives Hold Rating from Benchmark
Benchmark reissued their hold rating on shares of Maplebear (NASDAQ:CART – Free Report) in a research note issued to investors on Tuesday, Benzinga reports. A number of other research analysts also recently commented on the... More of this article »
BioNTech (NASDAQ:BNTX) Price Target Raised to $98.00 at TD Cowen
BioNTech (NASDAQ:BNTX – Free Report) had its target price lifted by TD Cowen from $95.00 to $98.00 in a research report sent to investors on Tuesday morning, Benzinga reports. TD Cowen currently has a hold rating on the stock. Several... More of this article »
Booking (NASDAQ:BKNG) Price Target Increased to $4,230.00 by Analysts at HSBC
Booking (NASDAQ:BKNG – Free Report) had its target price boosted by HSBC from $4,220.00 to $4,230.00 in a research report sent to investors on Tuesday morning, Benzinga reports. The brokerage currently has a buy rating on the... More of this article »
Beam Therapeutics (NASDAQ:BEAM) Receives “Outperform” Rating from Wedbush
Wedbush reiterated their outperform rating on shares of Beam Therapeutics (NASDAQ:BEAM – Free Report) in a report released on Tuesday, RTT News reports. They currently have a $57.00 price objective on the stock. A number of... More of this article »
BioCryst Pharmaceuticals (NASDAQ:BCRX) Given “Buy” Rating at Needham & Company LLC
Needham & Company LLC reaffirmed their buy rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) in a report released on Tuesday, Benzinga reports. The firm currently has a $12.00 target price on the... More of this article »
BioCryst Pharmaceuticals (NASDAQ:BCRX) Receives “Buy” Rating from HC Wainwright
HC Wainwright reiterated their buy rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) in a research note published on Tuesday, Benzinga reports. HC Wainwright currently has a $30.00 price target on the... More of this article »
BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Increased to $15.00 by Analysts at JMP Securities
BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) had its price objective boosted by JMP Securities from $14.00 to $15.00 in a report issued on Tuesday, Benzinga reports. JMP Securities currently has a market outperform rating... More of this article »
Axon Enterprise (NASDAQ:AXON) Receives Buy Rating from Needham & Company LLC
Needham & Company LLC reissued their buy rating on shares of Axon Enterprise (NASDAQ:AXON – Free Report) in a research report sent to investors on Tuesday morning, Benzinga reports. They currently have a $400.00 price target... More of this article »